Specific Targeting of HER2 Overexpressing Breast Cancer Cells with Doxorubicin-Loaded Trastuzumab-Modified Human Serum Albumin Nanoparticles
Identifieur interne : 001939 ( Main/Exploration ); précédent : 001938; suivant : 001940Specific Targeting of HER2 Overexpressing Breast Cancer Cells with Doxorubicin-Loaded Trastuzumab-Modified Human Serum Albumin Nanoparticles
Auteurs : Marion G. Anhorn [Allemagne] ; Sylvia Wagner [Allemagne] ; Jo Rg Kreuter [Allemagne] ; Klaus Langer [Allemagne] ; Hagen Von Briesen [Allemagne]Source :
- Bioconjugate Chemistry [ 1043-1802 ] ; 2008.
Abstract
Specific targeting of tumor cells to achieve higher drug levels in tumor tissue and to overcome cardiotoxic and other secondary effects is the major goal in cancer therapy. With trastuzumab as a humanized monoclonal antibody binding, the HER2 receptor specific targeting is possible. In the present study, target-oriented nanoparticles based on biodegradable human serum albumin (HSA) loaded with cytostatic drug doxorubicin were developed. The surface of the nanoparticles was modified by covalent attachment of trastuzumab. HER2 overexpressing breast cancer cells showed a good cellular binding and uptake of these nanoparticles. The specific transport of the cytostatic drug doxorubicin with this nanoparticulate formulation into the HER2 overexpressing breast cancer cells, their release, and biological activity was demonstrated. The results indicate that these cell-type specific drug-loaded nanoparticles could achieve an improvement in cancer therapy. To our knowledge, this is the first study demonstrating a specific trastuzumab-based targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded nanoparticles.
Url:
DOI: 10.1021/bc8002452
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000C31
- to stream Istex, to step Curation: 000C31
- to stream Istex, to step Checkpoint: 000844
- to stream Main, to step Merge: 001947
- to stream Main, to step Curation: 001939
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Specific Targeting of HER2 Overexpressing Breast Cancer Cells with Doxorubicin-Loaded Trastuzumab-Modified Human Serum Albumin Nanoparticles</title><author><name sortKey="Anhorn, Marion G" sort="Anhorn, Marion G" uniqKey="Anhorn M" first="Marion G." last="Anhorn">Marion G. Anhorn</name></author><author><name sortKey="Wagner, Sylvia" sort="Wagner, Sylvia" uniqKey="Wagner S" first="Sylvia" last="Wagner">Sylvia Wagner</name></author><author><name sortKey="Kreuter, Jo Rg" sort="Kreuter, Jo Rg" uniqKey="Kreuter J" first="Jo Rg" last="Kreuter">Jo Rg Kreuter</name></author><author><name sortKey="Langer, Klaus" sort="Langer, Klaus" uniqKey="Langer K" first="Klaus" last="Langer">Klaus Langer</name></author><author><name sortKey="Von Briesen, Hagen" sort="Von Briesen, Hagen" uniqKey="Von Briesen H" first="Hagen" last="Von Briesen">Hagen Von Briesen</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4C8B9D5473958F7107704775D32A2E73C5A1A09E</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1021/bc8002452</idno><idno type="url">https://api.istex.fr/ark:/67375/TPS-5S5D9FTJ-5/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000C31</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000C31</idno><idno type="wicri:Area/Istex/Curation">000C31</idno><idno type="wicri:Area/Istex/Checkpoint">000844</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000844</idno><idno type="wicri:doubleKey">1043-1802:2008:Anhorn M:specific:targeting:of</idno><idno type="wicri:Area/Main/Merge">001947</idno><idno type="wicri:Area/Main/Curation">001939</idno><idno type="wicri:Area/Main/Exploration">001939</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Specific Targeting of HER2 Overexpressing Breast Cancer Cells with Doxorubicin-Loaded Trastuzumab-Modified Human Serum Albumin Nanoparticles</title><author><name sortKey="Anhorn, Marion G" sort="Anhorn, Marion G" uniqKey="Anhorn M" first="Marion G." last="Anhorn">Marion G. Anhorn</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Fraunhofer Institute for Biomedical Engineering, Department of Cell Biology and Applied Virology, 66386 St. Ingbert, Germany, and Institute of Pharmaceutical Technology, Biocenter of Johann Wolfgang Goethe-University, 60438 Frankfurt/Main</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region><settlement type="city">Francfort-sur-le-Main</settlement></placeName></affiliation><affiliation></affiliation><affiliation></affiliation></author><author><name sortKey="Wagner, Sylvia" sort="Wagner, Sylvia" uniqKey="Wagner S" first="Sylvia" last="Wagner">Sylvia Wagner</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Fraunhofer Institute for Biomedical Engineering, Department of Cell Biology and Applied Virology, 66386 St. Ingbert, Germany, and Institute of Pharmaceutical Technology, Biocenter of Johann Wolfgang Goethe-University, 60438 Frankfurt/Main</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region><settlement type="city">Francfort-sur-le-Main</settlement></placeName></affiliation><affiliation></affiliation><affiliation></affiliation></author><author><name sortKey="Kreuter, Jo Rg" sort="Kreuter, Jo Rg" uniqKey="Kreuter J" first="Jo Rg" last="Kreuter">Jo Rg Kreuter</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Fraunhofer Institute for Biomedical Engineering, Department of Cell Biology and Applied Virology, 66386 St. Ingbert, Germany, and Institute of Pharmaceutical Technology, Biocenter of Johann Wolfgang Goethe-University, 60438 Frankfurt/Main</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region><settlement type="city">Francfort-sur-le-Main</settlement></placeName></affiliation><affiliation></affiliation></author><author><name sortKey="Langer, Klaus" sort="Langer, Klaus" uniqKey="Langer K" first="Klaus" last="Langer">Klaus Langer</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Fraunhofer Institute for Biomedical Engineering, Department of Cell Biology and Applied Virology, 66386 St. Ingbert, Germany, and Institute of Pharmaceutical Technology, Biocenter of Johann Wolfgang Goethe-University, 60438 Frankfurt/Main</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region><settlement type="city">Francfort-sur-le-Main</settlement></placeName></affiliation><affiliation></affiliation></author><author><name sortKey="Von Briesen, Hagen" sort="Von Briesen, Hagen" uniqKey="Von Briesen H" first="Hagen" last="Von Briesen">Hagen Von Briesen</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Fraunhofer Institute for Biomedical Engineering, Department of Cell Biology and Applied Virology, 66386 St. Ingbert, Germany, and Institute of Pharmaceutical Technology, Biocenter of Johann Wolfgang Goethe-University, 60438 Frankfurt/Main</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region><settlement type="city">Francfort-sur-le-Main</settlement></placeName></affiliation><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Allemagne</country></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Bioconjugate Chemistry</title><title level="j" type="abbrev">Bioconjugate Chem.</title><idno type="ISSN">1043-1802</idno><idno type="eISSN">1520-4812</idno><imprint><publisher>American Chemical Society</publisher><date type="e-published" when="2008-10-21">2008</date><date when="2008-12-17">2008</date><biblScope unit="vol">19</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="2321">2321</biblScope><biblScope unit="page" to="2331">2331</biblScope></imprint><idno type="ISSN">1043-1802</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1043-1802</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Specific targeting of tumor cells to achieve higher drug levels in tumor tissue and to overcome cardiotoxic and other secondary effects is the major goal in cancer therapy. With trastuzumab as a humanized monoclonal antibody binding, the HER2 receptor specific targeting is possible. In the present study, target-oriented nanoparticles based on biodegradable human serum albumin (HSA) loaded with cytostatic drug doxorubicin were developed. The surface of the nanoparticles was modified by covalent attachment of trastuzumab. HER2 overexpressing breast cancer cells showed a good cellular binding and uptake of these nanoparticles. The specific transport of the cytostatic drug doxorubicin with this nanoparticulate formulation into the HER2 overexpressing breast cancer cells, their release, and biological activity was demonstrated. The results indicate that these cell-type specific drug-loaded nanoparticles could achieve an improvement in cancer therapy. To our knowledge, this is the first study demonstrating a specific trastuzumab-based targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded nanoparticles.</div></front></TEI><affiliations><list><country><li>Allemagne</li></country><region><li>District de Darmstadt</li><li>Hesse (Land)</li></region><settlement><li>Francfort-sur-le-Main</li></settlement></list><tree><country name="Allemagne"><region name="Hesse (Land)"><name sortKey="Anhorn, Marion G" sort="Anhorn, Marion G" uniqKey="Anhorn M" first="Marion G." last="Anhorn">Marion G. Anhorn</name></region><name sortKey="Kreuter, Jo Rg" sort="Kreuter, Jo Rg" uniqKey="Kreuter J" first="Jo Rg" last="Kreuter">Jo Rg Kreuter</name><name sortKey="Langer, Klaus" sort="Langer, Klaus" uniqKey="Langer K" first="Klaus" last="Langer">Klaus Langer</name><name sortKey="Von Briesen, Hagen" sort="Von Briesen, Hagen" uniqKey="Von Briesen H" first="Hagen" last="Von Briesen">Hagen Von Briesen</name><name sortKey="Von Briesen, Hagen" sort="Von Briesen, Hagen" uniqKey="Von Briesen H" first="Hagen" last="Von Briesen">Hagen Von Briesen</name><name sortKey="Wagner, Sylvia" sort="Wagner, Sylvia" uniqKey="Wagner S" first="Sylvia" last="Wagner">Sylvia Wagner</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001939 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001939 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:4C8B9D5473958F7107704775D32A2E73C5A1A09E
|texte= Specific Targeting of HER2 Overexpressing Breast Cancer Cells with Doxorubicin-Loaded Trastuzumab-Modified Human Serum Albumin Nanoparticles
}}
| This area was generated with Dilib version V0.6.33. |  |